IHL.AX stock dropped to A$0.041 intraday on 03 Mar 2026, down -10.87%, as 61,360,016 shares traded by mid-session. The move makes Incannex Healthcare Limited (IHL.AX) one of the ASX’s most active names today, with a relative volume near 9.55 and a day range between A$0.041 and A$0.051. Traders are reacting to thin market capitalisation of A$14,255,927, a low 50-day average price of A$0.065, and an extensive clinical pipeline that often drives headline volatility. We outline the intraday drivers, financials, technical signals and a Meyka AI model forecast for IHL.AX stock.

Intraday action and trading metrics for IHL.AX stock

Today IHL.AX stock is trading at A$0.041, down -10.87%, with volume of 61,360,016, far above the average 6,427,691. The stock opened at A$0.047 and hit a session low of A$0.041, showing sellers dominated early trades. Relative volume of 9.55 flags aggressive intraday activity and makes IHL.AX one of the ASX most active names this session.

Financial snapshot and valuation metrics

Incannex shows a market cap of A$14,255,927 and 347,705,540 shares outstanding, with EPS of -1.30 and a negative PE. The company carries A$0.0217 cash per share and book value per share of A$0.0547, giving a price to book of 0.75. Current ratio is 9.02, reflecting strong short-term liquidity but negative operating cash flow per share of -0.01037, which highlights ongoing cash burn despite healthy working capital.

Pipeline updates and sector context

Incannex Healthcare (IHL.AX) develops cannabinoid and psychedelic therapies including IHL-42X and Psi-GAD that have reached Phase IIa trials, which keeps clinical milestones central to valuation. The healthcare sector on the ASX has lagged recently, down -5.73% YTD for the sector, so biotech clinical updates tend to create outsized moves in small-cap drug developers like IHL.AX. Investors typically watch trial readouts and regulatory news for short-term catalysts.

Technical outlook and trader signals

Price sits below the 50-day average (A$0.065) and 200-day average (A$0.103), indicating a bearish medium-term trend while intraday volume spike suggests high short-term interest. Day-range trading between A$0.041 and A$0.051 points to support at the session low and resistance near A$0.051. For active traders, the combination of low float and big volume can create rapid moves and elevated volatility.

Meyka grade, model forecast and analyst view

Meyka AI rates IHL.AX with a score of 65.04 out of 100 | Grade B | HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Analysts and the Meyka model flag pipeline value but note cash burn and execution risk as limiting near-term upside.

Risks, catalysts and trading strategy for most active names

Key risks for IHL.AX stock include trial setbacks, further dilution, and low market cap liquidity that can exaggerate moves. Catalysts include Phase II readouts, regulatory approvals, or licensing deals. For most active intraday traders, use strict risk controls: limit-size positions, watch the day VWAP, and set stop-losses given the stock’s high intraday volatility.

Final Thoughts

Key takeaways: IHL.AX stock is one of the ASX most active names intraday on 03 Mar 2026, trading at A$0.041 with 61,360,016 shares changing hands and a -10.87% session drop. Fundamentals show negative EPS -1.30, strong short-term liquidity with current ratio 9.02, and a price to book near 0.75. Meyka AI’s forecast model projects a near-term base case price target of A$0.080, implying an upside of 95.12% versus the current price AUD 0.041. Forecasts are model-based projections and not guarantees; they assume successful clinical progress and controlled dilution. Given small market capitalisation A$14.26M and ongoing R&D spend, the consensus trade is cautious. Traders seeking short-term moves should prioritise liquidity and stops, while longer-term investors should monitor trial milestones and cash runway before increasing exposure. Meyka AI provides this data as an AI-powered market analysis platform, not as personal advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.